Back to Bills

Medicare Covers Hereditary Cancer Testing

Full Title:
Reducing Hereditary Cancer Act

Summary#

This bill would change Medicare law to cover genetic testing and extra cancer prevention care for people who have, or may have, inherited (germline) cancer risk. The main goal is to make sure people with a personal or family history of hereditary cancer get testing, more frequent high-risk screening, and risk-reducing surgery when guidelines recommend it.

  • Main change: Medicare would cover germline (inherited) genetic tests for people with a personal or family history of a hereditary cancer gene mutation or a history that looks suspicious for hereditary cancer.
  • Guideline-based rules: Tests, screening schedules, and risk-reducing surgeries must follow evidence-based clinical practice guidelines from major oncology organizations. If guidelines conflict, a Medicare contractor will apply the least restrictive guideline.
  • Limits on repeat testing: Medicare would not pay for the same germline test more than once for an individual, unless the bill’s language is interpreted otherwise.
  • Screening frequency: For people found to have an inherited cancer mutation, Medicare must increase how often it pays for evidence-based cancer screening (mammography, breast MRI, colonoscopy, PSA, and similar tests), to at least once a year or as guideline-recommended.
  • Risk-reducing surgery: Surgeries that guideline authors say reduce cancer risk for someone with a hereditary mutation would be treated as reasonable and necessary and covered by Medicare.

What it means for you#

  • Medicare beneficiaries with a family or personal history of hereditary cancer: You could get covered genetic testing to check for inherited cancer mutations and, if positive, get more frequent screenings and covered risk-reducing surgeries when guidelines recommend them.
  • People with a known mutation in a blood relative: You would be eligible for the germline testing Medicare would cover if you meet the family-history or “suspicious” history language.
  • Health care providers (doctors, genetic counselors, hospitals): Providers could bill Medicare for guideline-based genetic testing, more frequent screenings for mutation carriers, and risk-reducing surgeries that guidelines support. Providers will need to document eligibility under the specified guidelines.
  • Medicare contractors (regional administrators): These contractors would decide which oncology guidelines count and, in cases of conflicting guidance, would pick the least restrictive guideline to follow. They would also apply the rule that limits payment for repeat germline testing.
  • Private insurers and non-Medicare patients: The bill changes only Medicare (Title XVIII). It does not directly change private insurance rules.

What is unclear:

  • The bill does not define what exactly counts as a “personal or family history suspicious for hereditary cancer.” It leaves interpretation to guidelines or Medicare contractors.
  • How to handle retesting when scientific knowledge or testing methods change is not spelled out, beyond the general exclusion for tests done “more than once.”

Expenses#

No publicly available information.

Possible fiscal effects (reasonable inferences from the bill text):

  • This could increase Medicare spending because more people would get genetic testing, more frequent screenings, and more preventive surgeries.
  • There could also be downstream cost offsets if more cancers are prevented or caught earlier, but the bill text does not provide estimates.
  • Administrative costs could rise for Medicare contractors and providers to implement guideline-based decisions and to track eligibility and frequency limits.

Proponents' View#

The bill appears intended to do the following:

  • Expand access to genetic testing for people with a family or personal history that suggests inherited cancer risk.
  • Align Medicare coverage with clinical practice guidelines from major oncology groups.
  • Let people with inherited mutations receive more frequent, guideline-based cancer screening and get risk-reducing surgery covered, which could prevent cancers that are otherwise likely to develop.
  • Make coverage decisions more consistent with current clinical guidance by directing Medicare contractors to follow nationally recognized oncology guidelines.

Opponents' View#

Possible concerns or trade-offs suggested by the bill’s design:

  • One concern is cost: broader coverage for testing, more frequent screening, and more preventive surgeries could raise Medicare spending, and the bill provides no fiscal estimate or offset.
  • The bill does not clearly define “suspicious” family or personal history. That could lead to inconsistent eligibility decisions or disputes between providers and Medicare contractors.
  • The rule barring payment for germline testing “more than once” could block clinically needed retesting when new tests or knowledge emerge, unless exceptions are created in practice.
  • Letting regional Medicare contractors choose which oncology organization to follow, and to pick the least restrictive guideline when guidelines conflict, could create variation in coverage across regions.
  • The bill does not specify how genetic counseling, documentation, or consent requirements will be handled, which could create administrative burdens for providers.